Cargando…

Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

PURPOSE: Treatment with the radiolabelled somatostatin analogue (177)Lu-octreotate results in tumour remission in 47% of patients with gastroenteropancreatic neuroendocrine tumours. Adding capecitabine to (177)Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now presen...

Descripción completa

Detalles Bibliográficos
Autores principales: van Essen, Martijn, Krenning, Eric P., Kam, Boen L., de Herder, Wouter W., van Aken, Maarten O., Kwekkeboom, Dik J.
Formato: Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668587/
https://www.ncbi.nlm.nih.gov/pubmed/18188559
http://dx.doi.org/10.1007/s00259-007-0688-7
_version_ 1782166186436329472
author van Essen, Martijn
Krenning, Eric P.
Kam, Boen L.
de Herder, Wouter W.
van Aken, Maarten O.
Kwekkeboom, Dik J.
author_facet van Essen, Martijn
Krenning, Eric P.
Kam, Boen L.
de Herder, Wouter W.
van Aken, Maarten O.
Kwekkeboom, Dik J.
author_sort van Essen, Martijn
collection PubMed
description PURPOSE: Treatment with the radiolabelled somatostatin analogue (177)Lu-octreotate results in tumour remission in 47% of patients with gastroenteropancreatic neuroendocrine tumours. Adding capecitabine to (177)Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now present the short-term toxicity profile of this novel combination. METHODS: Seven patients were treated with 7.4 GBq (177)Lu-octreotate and capecitabine (1650 mg/m(2) per day) for 2 weeks with an intended number of four cycles. Toxicity, and especially haematological and renal parameters, were monitored on a weekly basis for the first two cycles and 4 and 6 weeks after subsequent cycles. RESULTS: None of the patients had hand-foot syndrome. One patient had grade 1 stomatitis occurring after one of four cycles. Grade 3 or 4 leukopenia or neutropenia did not occur. One patient had grade 3 anaemia, but none had grade 4 anaemia. One patient had grade 2 thrombocytopenia after the fourth cycle, and one had grade 3 thrombocytopenia. Grade 4 thrombocytopenia did not occur. No significant changes in serum creatinine levels were observed. None of the patients had symptoms of cardiac ischaemia. CONCLUSIONS: Treatment with the combination of (177)Lu-octreotate and capecitabine was feasible and safe considering acute and subacute side effects. We therefore started a randomised, controlled clinical trial to compare this combination with (177)Lu-octreotate as single agent with regard to anti-tumour effects and side effects.
format Text
id pubmed-2668587
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-26685872009-04-23 Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours van Essen, Martijn Krenning, Eric P. Kam, Boen L. de Herder, Wouter W. van Aken, Maarten O. Kwekkeboom, Dik J. Eur J Nucl Med Mol Imaging Original Article PURPOSE: Treatment with the radiolabelled somatostatin analogue (177)Lu-octreotate results in tumour remission in 47% of patients with gastroenteropancreatic neuroendocrine tumours. Adding capecitabine to (177)Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now present the short-term toxicity profile of this novel combination. METHODS: Seven patients were treated with 7.4 GBq (177)Lu-octreotate and capecitabine (1650 mg/m(2) per day) for 2 weeks with an intended number of four cycles. Toxicity, and especially haematological and renal parameters, were monitored on a weekly basis for the first two cycles and 4 and 6 weeks after subsequent cycles. RESULTS: None of the patients had hand-foot syndrome. One patient had grade 1 stomatitis occurring after one of four cycles. Grade 3 or 4 leukopenia or neutropenia did not occur. One patient had grade 3 anaemia, but none had grade 4 anaemia. One patient had grade 2 thrombocytopenia after the fourth cycle, and one had grade 3 thrombocytopenia. Grade 4 thrombocytopenia did not occur. No significant changes in serum creatinine levels were observed. None of the patients had symptoms of cardiac ischaemia. CONCLUSIONS: Treatment with the combination of (177)Lu-octreotate and capecitabine was feasible and safe considering acute and subacute side effects. We therefore started a randomised, controlled clinical trial to compare this combination with (177)Lu-octreotate as single agent with regard to anti-tumour effects and side effects. Springer Berlin Heidelberg 2008-01-11 2008 /pmc/articles/PMC2668587/ /pubmed/18188559 http://dx.doi.org/10.1007/s00259-007-0688-7 Text en © The Author(s) 2007 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Original Article
van Essen, Martijn
Krenning, Eric P.
Kam, Boen L.
de Herder, Wouter W.
van Aken, Maarten O.
Kwekkeboom, Dik J.
Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
title Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
title_full Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
title_fullStr Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
title_full_unstemmed Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
title_short Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
title_sort report on short-term side effects of treatments with (177)lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668587/
https://www.ncbi.nlm.nih.gov/pubmed/18188559
http://dx.doi.org/10.1007/s00259-007-0688-7
work_keys_str_mv AT vanessenmartijn reportonshorttermsideeffectsoftreatmentswith177luoctreotateincombinationwithcapecitabineinsevenpatientswithgastroenteropancreaticneuroendocrinetumours
AT krenningericp reportonshorttermsideeffectsoftreatmentswith177luoctreotateincombinationwithcapecitabineinsevenpatientswithgastroenteropancreaticneuroendocrinetumours
AT kamboenl reportonshorttermsideeffectsoftreatmentswith177luoctreotateincombinationwithcapecitabineinsevenpatientswithgastroenteropancreaticneuroendocrinetumours
AT deherderwouterw reportonshorttermsideeffectsoftreatmentswith177luoctreotateincombinationwithcapecitabineinsevenpatientswithgastroenteropancreaticneuroendocrinetumours
AT vanakenmaarteno reportonshorttermsideeffectsoftreatmentswith177luoctreotateincombinationwithcapecitabineinsevenpatientswithgastroenteropancreaticneuroendocrinetumours
AT kwekkeboomdikj reportonshorttermsideeffectsoftreatmentswith177luoctreotateincombinationwithcapecitabineinsevenpatientswithgastroenteropancreaticneuroendocrinetumours